$1.29-1.9%Nov 13 close
Reported results on November 12, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $4.4M | $9.2M | -52.32% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Equillium, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal immunoregulatory mechanism of action without broad immune suppression, designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product. Equillium is also evaluating the potential of EQ504 for additional indications, including inflammatory lung diseases through inhaled formulations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Equillium, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.